Abstract
About 29 of 33 million persons living with human immunodeficiency virus (HIV) or the acquired immunodeficiency syndrome (AIDS) (PLHA) worldwide in 2009 reside in resource-limited countries. The burden of cancer in this population is substantial, although there is much we still do not know about the epidemiology of various HIV-associated tumors in these regions. Access to life-extending combination antiretroviral therapy (cART), which has been rapidly expanding since 2000, has improved survival to nearly normal life expectancy, including in resource-limited countries where about 30 % of PLHA are receiving cART. The improvements in survival with HIV, however, are occurring at the expense of increased incidence of chronic co-morbidities including cancer in PLHA on cART. Sparse data about risk of cancer in PLHA in resource-limited countries complicates efforts to evaluate this concern. Cancer is diagnosed in about 30 % of PLHA in developed countries. Cancers in PLHA are historically categorized as “AIDS-defining” cancer (ADC) or “non-AIDS-defining” cancers (NADC). ADCs include Kaposi sarcoma (KS), aggressive non-Hodgkin lymphoma (NHL), including Burkitt lymphoma (BL), and invasive cervical cancer. These cancers have a viral etiology and are more likely to be associated with degree or duration of immunosuppression. NADCs include Hodgkin lymphoma, anogenital, liver, and lung cancer. Most of these cancers have a viral etiology or are associated with lifestyle factors, e.g., cigarette smoking or injection drug use, which are more prevalent in PLHA. These cancers often occur in spite of sustained immune-restoration. Thus, NADCs have assumed greater importance as PLHA survive longer and ADCs proportionately decrease. Cancer is diagnosed in fewer than 5 % of PLHA in resource-limited countries. This rate is likely a gross underestimate, and is also affected by competing mortality from endemic infectious diseases such as malaria and tuberculosis. The low access to diagnostic services in low resource settings may also mean that a notable fraction of cancers remain undiagnosed in PLHA. Increasing access to affordable cART in resource-limited settings is likely to rapidly reduce infectious co-morbidities such as tuberculosis and thus amplify the importance of cancer in PLHA. Studies of PLHA in resource-limited countries are needed to characterize the additional cancer burden in PLHA to inform public health policy and knowledge about cancer etiology in different populations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ablashi D, Chatlynne L, et al. Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer. 1999;81:893–7.
AIDS Epidemic Update. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO); November 2009.
Amir H, Kaaya EE, et al. Kaposi’s sarcoma before and during a human immunodeficiency virus epidemic in Tanzanian children. Pediatr Infect Dis J. 2001;20:518–21.
Ateenyi-Agaba C. Conjunctival squamous-cell carcinoma associated with HIV infection in Kampala, Uganda. Lancet. 1995;345:695–6.
Bayley AC. Aggressive Kaposi’s sarcoma in Zambia, 1983. Lancet. 1984;1:1318–20.
Bayley AC. Occurrence, clinical behaviour and management of Kaposi’s sarcoma in Zambia. Cancer Surv. 1991;10:53–71.
Biggar RJ, Chaturvedi AK, et al. Cancer risk in persons with HIV/AIDS in India: a review and future directions for research. Infect Agent Cancer. 2009;4:4.
Boshoff C. Kaposi’s sarcoma and other HHV-8-associated tumors. In: Goedert JJ, editor. Infectious causes of cancer: targets for intervention. New York: Springer; 2000; p. 588.
Chokunonga E, Borok MZ, et al. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991–2010. Int J Cancer. 2013;133:721–9.
de Martel C, Ferlay J, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.
Dedicoat M, Newton R. Review of the distribution of Kaposi’s sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi’s sarcoma. Br J Cancer. 2003;88:1–3.
Dhir AA, Sawant S, et al. Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control. 2008;19:147–53.
Downing RG, Eglin RP, et al. African Kaposi’s sarcoma and AIDS. Lancet. 1984;1:478–80.
Hutt MS. Classical and endemic form of Kaposi’s sarcoma. A review. Antibiot Chemother. 1983;32:12–7.
Hutt MS, Burkitt D. Geographical distribution of cancer in East Africa: a new clinicopathological approach. Br Med J. 1965;2:719–22.
Jaffe HW, De Stavola BL, et al. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS. 2011;25:1395–403.
Lucas SB, Diomande M, et al. HIV-associated lymphoma in Africa: an autopsy study in Cote d’Ivoire. Int J Cancer. 1994;59:20–4.
Mbulaiteye SM, Goedert JJ. Transmission of Kaposi sarcoma-associated herpesvirus in sub-Saharan Africa. AIDS. 2008;22:535–7.
Mbulaiteye SM, Katabira ET, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer. 2006;118:985–90.
Mbulaiteye SM, Bhatia K, et al. HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data. Infect Agent Cancer. 2011;6:16.
Mutalima N, Molyneux EM, et al. Impact of infection with human immunodeficiency virus-1 (HIV) on the risk of cancer among children in Malawi - preliminary findings. Infect Agent Cancer. 2010;5:5.
Mwanda WO, Orem J, et al. Clinical characteristics of Burkitt’s lymphoma from three regions in Kenya. East Afr Med J. 2005;82:S135–43.
Newton R, Ngilimana PJ, et al. Cancer in Rwanda. Int J Cancer. 1996;66:75–81.
Newton R, Ziegler J, et al. A case-control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda. Int J Cancer. 2001;92:622–7.
Ogwang MD, Zhao W, et al. Accuracy of Burkitt lymphoma diagnosis in constrained pathology settings: importance to epidemiology. Arch Pathol Lab Med. 2011;135:445–50.
Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer. 2006;6:603–12.
Parkin DM, Wabinga H, et al. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS. 1999;13:2563–70.
Sampaio J, Brites C, et al. AIDS related malignancies in Brazil. Curr Opin Oncol. 2007;19: 476–8.
Sasco AJ, Jaquet A, et al. The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One. 2010;5:e8621.
Sitas F, Pacella-Norman R, et al. The spectrum of HIV-1 related cancers in South Africa. Int J Cancer. 2000;88:489–92.
Sriplung H, Parkin DM. Trends in the incidence of acquired immunodeficiency syndrome-related malignancies in Thailand. Cancer. 2004;101:2660–6.
Stefan DC, Stones D, et al. Burkitt lymphoma in South African children: one or two entities? Transfus Apher Sci. 2011;44:191–4.
Stein L, Urban MI, et al. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995–2004. Int J Cancer. 2008;122:2260–5.
Sutcliffe S, Taha TE, et al. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. J Acquir Immune Defic Syndr. 2002;31:90–7.
Sylla BS, Wild CP. A million Africans a year dying from cancer by 2030: what can cancer research and control offer to the continent? Int J Cancer. 2012;130:245–50.
Tanon A, Jaquet A, et al. The spectrum of cancers in West Africa: associations with human immunodeficiency virus. PLoS One. 2012;7:e48108.
Wabinga HR, Parkin DM, et al. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer. 2000;82:1585–92.
Wright DH. What is Burkitt’s lymphoma and when is it endemic? Blood. 1999;93:758.
Yoshioka MC, Alchorne MM, et al. Epidemiology of Kaposi’s sarcoma in patients with acquired immunodeficiency syndrome in Sao Paulo, Brazil. Int J Dermatol. 2004;43:643–7.
Zhang YX, Gui XE, et al. Cancer in cohort of HIV-infected population: prevalence and clinical characteristics. J Cancer Res Clin Oncol. 2011;137:609–14.
Ziegler JL. Endemic Kaposi’s sarcoma in Africa and local volcanic soils. Lancet. 1993;342: 1348–51.
Ziegler JL, Dorfman RF. Kaposi’s sarcoma: pathophysiology and clinical management. New York: M. Dekker; 1988.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Mbulaiteye, S.M. (2014). HIV Cancers in Resource-Limited Regions. In: Yarchoan, R. (eds) Cancers in People with HIV and AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0859-2_4
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0859-2_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0858-5
Online ISBN: 978-1-4939-0859-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)